22 terminated. 22 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Terminated 22 |
Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia evolocumab, placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Amgen | 259 | 2019-05-09 | 2023-03-27 |
| A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia Evacetrapib, Ezetimibe, Atorvastatin - Hypercholesterolemia | Phase 3 | Terminated | Eli Lilly and Company | 149 | 2015-01-01 | 2018-10-09 |
| A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia Evacetrapib, Placebo - Hypercholesterolemia | Phase 3 | Terminated | Eli Lilly and Company | 54 | 2014-11-01 | 2018-10-09 |
| Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care Placebo, Eprotirome - Heterozygous Familial Hypercholesterolaemia | Phase 3 | Terminated | Karo Bio AB | 236 | 2011-10-01 | 2012-09-03 |
| Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM) - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1139 | 2011-05-01 | 2019-02-06 |
| Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill - Hypercholesterolemia | Phase 3 | Terminated | University of California, Los Angeles | 13 | 2011-03-22 | 2019-02-12 |
| Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) Extended-release niacin/laropiprant (ERN/LRPT), Placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1173 | 2011-03-01 | 2024-05-22 |
| A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT) - Primary Hypercholesterolemia, Dyslipidemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 977 | 2011-02-04 | 2018-08-16 |
| Ezetimibe in Patients Hypo-responsive to Statins Ezetimibe, Atorvastatin - High Cholesterol, Coronary Artery Disease | Phase 3 | Terminated | University of California, San Diego | 2 | 2009-09-01 | 2019-08-21 |
| Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia AVE5530, Placebo - Hypercholesterolemia | Phase 3 | Terminated | Sanofi | 643 | 2008-10-01 | 2016-05-16 |
| Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia AVE5530, atorvastatin, placebo - Hypercholesterolemia | Phase 3 | Terminated | Sanofi | 1736 | 2008-08-01 | 2016-05-16 |
| Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia 25 mg/day AVE5530, 50 mg/day AVE5530, placebo - Hypercholesterolemia | Phase 3 | Terminated | Sanofi | 1015 | 2008-07-01 | 2016-05-16 |
| Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia AVE5530, Placebo - Hypercholesterolemia | Phase 3 | Terminated | Sanofi | 826 | 2008-07-01 | 2016-05-16 |
| Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia Lapaquistat acetate, Placebo - Hypercholesterolemia | Phase 3 | Terminated | Takeda | 657 | 2007-10-01 | 2012-05-24 |
| INdians Followed for INtensive Lipid Lowering Treatment and Its safetY ezetimibe, Comparator: Simvastatin 20, 40 and 80 mg, Comparator: Atorvastatin - Hypercholesterolemia | Phase 3 | Terminated | Sunnybrook Health Sciences Centre | 64 | 2007-08-01 | 2011-07-28 |
| Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia Lapaquistat acetate and stable statin therapy, Stable statin therapy - Hypercholesterolemia | Phase 3 | Terminated | Takeda | 411 | 2007-07-01 | 2016-06-22 |
| Evaluation of Atorvastatin Treatment on Carotid Plaque. Atorvastatin - Cardiovascular Diseases | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 160 | 2007-01-01 | 2021-02-18 |
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). torcetrapib/atorvastatin, simvastatin - Hyperlipidemia, Dyslipidemia | Phase 3 | Terminated | Pfizer | 640 | 2006-01-01 | 2012-02-17 |
| Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia Lapaquistat acetate and stable statin therapy, Stable statin therapy - Hypercholesterolemia | Phase 3 | Terminated | Takeda | 649 | 2005-11-01 | 2012-05-24 |
| Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment - Hypercholesterolemia | Phase 3 | Terminated | Takeda | 44 | 2005-11-01 | 2012-05-24 |
Showing 20 of 22. Sign in to see all of them.
Dyslipidemias (5) · Hyperlipidemias (5) · Coronary Artery Disease (2) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Thyroid Diseases (1)
Lipid Metabolism Disorders (22) · Metabolic Diseases (22) · Nutritional and Metabolic Diseases (22) · Dyslipidemias (17) · Hyperlipidemias (17) · Arterial Occlusive Diseases (3) · Arteriosclerosis (3) · Cardiovascular Diseases (3) · Vascular Diseases (3) · Coronary Disease (2) · Heart Diseases (2) · Myocardial Ischemia (2) · Endocrine System Diseases (1)
Atorvastatin (7) · Simvastatin (6) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (4) · Ezetimibe (4) · MK-0524 (3) · Rosuvastatin Calcium (2) · evacetrapib (2) · 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (1) · Ezetimibe, Simvastatin Drug Combination (1) · Fluvastatin (1) · Lovastatin (1) · Niacin (1) · Pravastatin (1) · Sugars (1) · evolocumab (1)
Sanofi (4) · Takeda (4) · Merck Sharp & Dohme LLC (3) · Eli Lilly and Company (2) · Amgen (1) · Drug Commission of the German Medical Association (1) · Karo Bio AB (1) · Organon and Co (1) · Pfizer (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Sunnybrook Health Sciences Centre (1) · University of California, Los Angeles (1) · University of California, San Diego (1)
United States (11) · Canada (5) · Israel (4) · France (3) · Netherlands (3) · Russia (3) · Australia (2) · Belgium (2) · Czechia (2) · Hungary (2) · Japan (2) · Norway (2) · Poland (2) · Puerto Rico (2) · Slovakia (2)
David Heber, MD, PhD (1) · Davidson Michael, MD (1) · Heiner K. Berthold, MD, PhD (1) · John Kastelein, Professor (1) · Ori Ben-Yehuda, MD (1) · Zhaoping Li, MD, PhD (1)
PMID 21518985, PMID 16705107, PMID 24731671
2005 (2)